55I LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

55I LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.24M	Buy	+1,803	New	+$1.13M	0.03%	229

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

55I LLC's REGN Position: Q3 2022 in Review

55I LLC opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2022: 1,803 shares worth $1.24M. The stake represents 0.03% of the portfolio and ranks #229 among its holdings.

1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

55I LLC held 1,803 shares of Regeneron Pharmaceuticals worth $1.24M as of Q3 2022.
Regeneron Pharmaceuticals was a new 55I LLC position in Q3 2022.
Regeneron Pharmaceuticals made up 0.03% of 55I LLC's portfolio in Q3 2022, its #229 holding.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on 55I LLC's 13F filing for Q3 2022, filed 14 Nov 2022.